SG11202003323TA - Ildr2 antagonists and combinations thereof - Google Patents

Ildr2 antagonists and combinations thereof

Info

Publication number
SG11202003323TA
SG11202003323TA SG11202003323TA SG11202003323TA SG11202003323TA SG 11202003323T A SG11202003323T A SG 11202003323TA SG 11202003323T A SG11202003323T A SG 11202003323TA SG 11202003323T A SG11202003323T A SG 11202003323TA SG 11202003323T A SG11202003323T A SG 11202003323TA
Authority
SG
Singapore
Prior art keywords
combinations
ildr2
antagonists
ildr2 antagonists
Prior art date
Application number
SG11202003323TA
Other languages
English (en)
Inventor
Lars Röse
Uwe Gritzan
Julia Hütter
Spencer Liang
Andrew Pow
John Hunter
Ofer Levy
Ilan Vaknin
Original Assignee
Bayer Ag
Bayer Pharma AG
Compugen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Bayer Pharma AG, Compugen Ltd filed Critical Bayer Ag
Publication of SG11202003323TA publication Critical patent/SG11202003323TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11202003323TA 2017-11-30 2018-11-28 Ildr2 antagonists and combinations thereof SG11202003323TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762592913P 2017-11-30 2017-11-30
PCT/EP2018/082779 WO2019105972A1 (en) 2017-11-30 2018-11-28 Ildr2 antagonists and combinations thereof

Publications (1)

Publication Number Publication Date
SG11202003323TA true SG11202003323TA (en) 2020-05-28

Family

ID=64559680

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202003323TA SG11202003323TA (en) 2017-11-30 2018-11-28 Ildr2 antagonists and combinations thereof

Country Status (15)

Country Link
US (1) US11655297B2 (zh)
EP (1) EP3717007A1 (zh)
JP (1) JP7350740B2 (zh)
KR (1) KR20200096223A (zh)
CN (1) CN111655287A (zh)
AR (1) AR113850A1 (zh)
AU (1) AU2018376231A1 (zh)
BR (1) BR112020010767A2 (zh)
CA (1) CA3083675A1 (zh)
IL (1) IL274751A (zh)
MX (1) MX2020005483A (zh)
RU (1) RU2020121533A (zh)
SG (1) SG11202003323TA (zh)
TW (1) TW201934119A (zh)
WO (1) WO2019105972A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3952910A1 (en) * 2019-04-11 2022-02-16 Bayer Aktiengesellschaft Combinations of anti-ildr2 antibodies and pd-1 antagonists
CN111574626B (zh) * 2020-05-27 2021-12-31 斯爱玲 一种ildr2抗体、其药物组合物及其用途
CN111558038B (zh) * 2020-05-27 2022-04-19 北京加美康联健康管理集团有限公司 一种用于癌症治疗的免疫检查点抑制剂
AU2021353004A1 (en) 2020-09-30 2023-04-13 Nobell Foods, Inc. Recombinant milk proteins and food compositions comprising the same
US10947552B1 (en) 2020-09-30 2021-03-16 Alpine Roads, Inc. Recombinant fusion proteins for producing milk proteins in plants
US10894812B1 (en) 2020-09-30 2021-01-19 Alpine Roads, Inc. Recombinant milk proteins

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
SG195524A1 (en) 2003-11-06 2013-12-30 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
MY146381A (en) * 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
HUE042982T2 (hu) 2007-09-04 2019-07-29 Compugen Ltd Polipeptidek és polinukleotidok, és alkalmazásuk drogcélpontként drogok és biológiai szerek elõállítására
CA2805024A1 (en) * 2010-06-30 2012-01-05 Compugen Ltd. Polypeptides and uses thereof as a drug for treatment of multiples sclerosis, rheumatoid arthritis and other autoimmune disorders
US9428574B2 (en) 2011-06-30 2016-08-30 Compugen Ltd. Polypeptides and uses thereof for treatment of autoimmune disorders and infection
US20170233473A1 (en) 2014-05-27 2017-08-17 Compugen Ltd. C10rf32 antibodies, and uses thereof for treatment of cancer
CA2848985A1 (en) * 2012-02-01 2013-08-08 Compugen Ltd. C10rf32 antibodies, and uses thereof for treatment of cancer
US9682123B2 (en) 2013-12-20 2017-06-20 The Trustees Of Columbia University In The City Of New York Methods of treating metabolic disease
RS61711B1 (sr) 2014-04-10 2021-05-31 Daiichi Sankyo Co Ltd Anti-her3 antitelo-lek konjugat
US10759861B2 (en) 2015-09-16 2020-09-01 Ablexis, Llc Anti-CD115 antibodies

Also Published As

Publication number Publication date
TW201934119A (zh) 2019-09-01
MX2020005483A (es) 2020-08-27
IL274751A (en) 2020-07-30
AU2018376231A1 (en) 2020-05-07
US20200369769A1 (en) 2020-11-26
JP7350740B2 (ja) 2023-09-26
EP3717007A1 (en) 2020-10-07
AR113850A1 (es) 2020-06-17
RU2020121533A (ru) 2021-12-30
CA3083675A1 (en) 2019-06-06
CN111655287A (zh) 2020-09-11
US11655297B2 (en) 2023-05-23
WO2019105972A1 (en) 2019-06-06
JP2021504404A (ja) 2021-02-15
BR112020010767A2 (pt) 2020-11-24
KR20200096223A (ko) 2020-08-11

Similar Documents

Publication Publication Date Title
IL293377A (en) hsd17b13 variants and their uses
IL264813B (en) 2-oxo-imidazopyridines and their use
IL274751A (en) ILDR2 antagonists and combinations thereof
HK1250146A1 (zh) 抗前-bcr拮抗劑和方法
IL292488B1 (en) Pyridineamine-pyridone and pyrimidineamine-pyridone compounds
GB2563869B (en) Materials and methods
IL292692A (en) mrgprx2 antagonists and their uses
IL265531A (en) N 3 -cyclically substituted thienouraciles and use thereof
IL275211A (en) Fast and flexible segment chains - division
IL269836B (en) Converted N-arylethyl-2-aminoquinoline-4-carboxamides and their use
HK1246288A1 (zh) S1pr2拮抗劑及其用途
IL292482B2 (en) Azaindolylpyridone and diazaindolylpyridone compounds
GB201700404D0 (en) Compounds and composistions
IL269843B (en) Converted N-arylethyl-2-arylquinoline-4-carboxamides and their use
IL292693A (en) mrgprx2 antagonists and their uses
ZA201807767B (en) Angiotensin-1-receptor antagonists
GB201707279D0 (en) Multiearphones and polyearphones
GB201712266D0 (en) polypeptides and uses thereof
GB201712268D0 (en) Polypeptides and uses thereof
PT3464324T (pt) Antagonistas de recetores da angiotensina-1
GB2545167B (en) Cloches and use thereof
GB201613142D0 (en) Polypeptides and uses thereof
GB201613143D0 (en) Polypeptides and uses thereof